$74.1 Million is the total value of CAXTON CORP's 19 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SNTA | Buy | SYNTA PHARMACEUTICALS CORP | $64,500,000 | -22.0% | 37,069,140 | +0.0% | 87.00% | -0.5% |
DNAI | New | PRONAI THERAPEUTICS INC | $938,000 | – | 45,719 | +100.0% | 1.26% | – |
GDX | New | MARKET VECTORS ETF TRcall | $436,000 | – | 31,733 | +100.0% | 0.59% | – |
NSL | Buy | NUVEEN SR INCOME FD | $417,000 | +109.5% | 70,518 | +126.4% | 0.56% | +166.4% |
SLRC | New | SOLAR CAP LTD | $318,000 | – | 20,098 | +100.0% | 0.43% | – |
EVF | Buy | EATON VANCE SR INCOME TRsh ben int | $310,000 | +1.0% | 52,889 | +6.9% | 0.42% | +28.6% |
FRA | Buy | BLACKROCK FLOAT RATE OME STR | $309,000 | +107.4% | 23,888 | +117.3% | 0.42% | +163.9% |
JRO | New | NUVEEN FLTNG RTE INCM OPP FD | $281,000 | – | 28,207 | +100.0% | 0.38% | – |
MDLY | Buy | MEDLEY MGMT INC | $233,000 | -30.0% | 35,259 | +25.2% | 0.31% | -10.8% |
SCM | New | STELLUS CAP INVT CORP | $213,000 | – | 21,155 | +100.0% | 0.29% | – |
AGRX | Buy | AGILE THERAPEUTICS INC | $155,000 | +2.6% | 23,035 | +31.2% | 0.21% | +30.6% |
CMFN | New | CM FIN INC | $150,000 | – | 14,658 | +100.0% | 0.20% | – |
SNTA | Buy | SYNTA PHARMACEUTICALS CORPcall | $99,000 | -14.7% | 57,000 | +9.6% | 0.13% | +8.9% |
FSC | New | FIFTH STREET FINANCE CORP | $98,000 | – | 15,867 | +100.0% | 0.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
CM FIN INC | 16 | Q1 2019 | 7.8% |
SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.